Copyright ©2013 Baishideng.
World J Hematol. May 6, 2013; 2(2): 20-43
Published online May 6, 2013. doi: 10.5315/wjh.v2.i2.20
Table 6 Low, intermediate and high thrombohemorrhagic risk stratification of essential thrombocythemia patients and a flexible approach towards therapeutic implications with reference to platelet counts including essential thrombocythemia patients with features of early polycythemia vera in blood and bone marrow (prodromal polycythemia vera)
Platelets (400-1500 × 109/L)Platelets (400-1000 × 109/L)Platelets (400-1000 × 109/L)Platelets (> 1500 × 109/L)
Low riskLow riskHigh riskHigh risk
Completely asymptomaticMicrovascular disturbances only1Major thrombosis, and/or bleeding> 1000 × 109/L and minor thrombosis/bleeding = high
No vascular riskNo vascular riskVascular riskNo vascular risk
No bleeding riskNo bleeding risk
Age < 65 yr2Age < 65 yr except2Age > 65 yr except3All ages
Aspirin uncertainLow dose aspirinPlatelet reduction to normal or near normalPlatelet reduction to < 1000 × 109/L
Wait and see?50 to 100 mg/d
Intermediate risk
Aspirin primary prevention?Microvascular disturbances and platelet count between 1000 and 1500 × 109/L with clear indication aspirin1, →side effects (platelet reduction)Continue aspirin1When platelets < 1000 × 109/L add aspirin
ET patients and their physician usually prefer the use of low dose aspirin